115 related articles for article (PubMed ID: 25503393)
1. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies.
Lee SY; Kim DW; Lee HS; Ihn MH; Oh HK; Park DJ; Kim HH; Kang SB
Oncology; 2015; 88(4):234-40. PubMed ID: 25503393
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.
Wei XL; Wang DS; Xi SY; Wu WJ; Chen DL; Zeng ZL; Wang RY; Huang YX; Jin Y; Wang F; Qiu MZ; Luo HY; Zhang DS; Xu RH
World J Gastroenterol; 2014 Dec; 20(48):18404-12. PubMed ID: 25561809
[TBL] [Abstract][Full Text] [Related]
3. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.
Abe H; Hayashi A; Kunita A; Sakamoto Y; Hasegawa K; Shibahara J; Kokudo N; Fukayama M
Int J Clin Exp Pathol; 2015; 8(3):2763-70. PubMed ID: 26045782
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma.
Kim MJ; Gu MJ; Chang HK; Yu E
Histopathology; 2015 Mar; 66(4):508-16. PubMed ID: 25400081
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
9. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer.
Zhu YP; Sheng LL; Wu J; Yang M; Cheng XF; Wu NN; Ye XB; Cai J; Wang L; Shen Q; Wu JQ
Hum Pathol; 2018 Aug; 78():28-35. PubMed ID: 29689245
[TBL] [Abstract][Full Text] [Related]
10. Altered ARID1A expression in colorectal cancer.
Erfani M; Hosseini SV; Mokhtari M; Zamani M; Tahmasebi K; Alizadeh Naini M; Taghavi A; Carethers JM; Koi M; Brim H; Mokarram P; Ashktorab H
BMC Cancer; 2020 Apr; 20(1):350. PubMed ID: 32334542
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
12. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
14. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of ARID1A negative expression in gastric cancer.
Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.
Aso T; Uozaki H; Morita S; Kumagai A; Watanabe M
Anticancer Res; 2015 Dec; 35(12):6819-27. PubMed ID: 26637902
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of ARID1A in gastric cancer and paired adjacent noncancerous tissues].
Zhang X; Wang S; Liu N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jan; 33(1):77-80. PubMed ID: 28031120
[TBL] [Abstract][Full Text] [Related]
19. Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer.
Kishida Y; Oishi T; Sugino T; Shiomi A; Urakami K; Kusuhara M; Yamaguchi K; Kitagawa Y; Ono H
Am J Clin Pathol; 2019 Sep; 152(4):463-470. PubMed ID: 31263894
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Inducible Factor 1α and AT-Rich Interactive Domain-Containing Protein 1A Expression in Pituitary Adenomas: Association with Pathological, Clinical, and Radiological Features.
Kinali B; Senoglu M; Karadag FK; Karadag A; Middlebrooks EH; Oksuz P; Sandal E; Turk C; Diniz G
World Neurosurg; 2019 Jan; 121():e716-e722. PubMed ID: 30292665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
